During these challenging financial times, it is critical to bring together finance executives for discussion and debate between top pharmaceutical, biotech, medical device and diagnostic companies. Through a combination of thought-provoking keynote presentations, round-table discussions highlighting point-counterpoint perspectives and pre-scheduled networking meetings, participants from provider partner corporations and industry alike will walk away with tangible methods of addressing their critical financial challenges. Forum sessions will highlight a variety of the issues that finance executives currently face in the industry.
Rising concerns over the stability of the euro, evolving national healthcare systems, and greatly reduced access to potential credit is squeezing organizations in many ways. Thus, the role of CFOs has become increasingly crucial for organizations as they work to weather the storm of political and financial instability, requiring the strategic insight and financial finesse of thoughtful and forward thinking financial executives.
The ongoing credit-crunch and market instability has required many organizations to rethink their asset management strategies and retain higher levels of capital than previously required. It has also challenged many organizations to flex their financial management plans as credit has been scarce.
Ongoing changes in health policy and reimbursement strategies for each European Union state will be addressed, as the challenge of fiscal forecasting and budgeting is made even more difficult as country-by-country healthcare systems evolve their own reimbursement policies and rates.
Due diligence and the role of the finance executives during merger & acquisition activity is a critical topic that will be addressed from a variety of perspectives, with the buy-side and seller-side represented during the program agenda. Utilization of M&A as an exit strategy for smaller start-up corporations will also be covered in tracked sessions focusing on topics on the various sizes and capabilities of organizations.
In addition, no financial conference would be complete without discussions highlighting regulatory trends, transfer pricing, IFRS and tax planning; all of which will be addressed across the three days of the Forum. This forum will provide an executive-level perspective on the many dire challenges that Chief Financial Officers face in this uncertain environment. With the insight of our provider partner organizations, who provide strategic, best-in-class services, this program will provide participants with an opportunity to truly better their financial standing.
When: June 5 - 7, 2011
Where: Munich, Germany
Who: This conference is ideal for senior-level European financial executives within the pharmaceutical, biotech, medical device & diagnostic industries.
Presenting organizations include: Activaero, AdaptImmune, Amsterdam Molecular Therapeutics, Bausch & Lomb, BioDeutschland, Biotronik, Carefusion, Curetis, Genpact, Histoscanning, InFlaRx, Medtronic, Merck Serono, Molecular Partners, NGBI Ventures, Nobel Biocare, Novartis, Silence Therapeutics, Simmons & Simmons LLP, Sofinnova Partners, Sorin Group & Vivacta
About the Organizer
Q1 Productions has over 25 years of combined event production experience, with previous roles in international Sales Management, Productions and Operations. Focusing on new or pending legislative issues, enhanced business processes or technologies that will drive efficiency and customer service, our conference programs provide solutions to the urgent needs of our attendees.
q1productions/eventPages/event_F-8005.php
Source:
Q1 Productions